


Two Oral Delivery Platforms,
Two Peptides (BPC-157 and KPV)
We 3D-print medicines at room temperature, with no heat and no UV, on two delivery platforms. Our initial pipeline is peptides, which usually must be injected: under 1% of a swallowed dose is absorbed. Since October 2026, HHS lets 503A pharmacies compound six peptides; only KPV and BPC-157 are covered for oral use.

Colon-targeted
The patent-pending pill-in-pill holds through the stomach and releases its dose in the colon, where gut disease is.

Mucoadhesive Oral films
The film sticks to the inside of the cheek. The dose passes through the cheek lining into the bloodstream, bypassing the gut and first-pass liver metabolism.
Our focus: BPC-157 and KPV
Both peptides are being developed on both platforms.
Explore our peptide pipelineCompounded products are patient-specific prescriptions and are not FDA-approved. No efficacy claims are made. The oral film is in development and its regulatory pathway has not been established. Images are renders.

